二次性副甲状腺機能こう進症（２°ＨＰＴ）の発症予防に関する１α（ＯＨ）Ｄ３至適投与量の臨床的検討

森 忠三, 海江田 浩之, 竹内 正気

doi:10.4009/jsdt1985.25.881

書誌事項

タイトル別名

Clinical research on the optimum dosage of 1.ALPHA.(OH)D3(1.ALPHA.D3) for preventing secondary hyperparathyroidism (2.DEG.HPT).

説明

Recently we have reduced the dosage of 1α D₃ for hypercalcemia not only by changing the calcium concentration of dialysates ([D]_Ca) but also by using CaCO₃. In order to clarify the optimum dosage of 1αD₃ for preventing 2°HPT, we performed a retrospective study as follows. Fifty maintenance hemodialysis patients were divided into several groups according to the conditions of administration of CaCO₃ and 1α D₃, and to [D]_ca. In each group, the changes in calcium and bone metabolites were examined. The results showed that administration of 0.75-1.0μg/day of 1α D₃ seemed to prevent an increase in serum C-PTH at normal serum Ca levels (mean 9.6mg/dl), but administration of a lower dosage (<0.5μg/day) was associated with a higher serum Ca level (mean 10.0mg/dl), and moreover, the serum P level tended to increase at the same time. Accordingly there is a danger of ectopic calcification. Therefore, we recommend the administration of 0.75-1.0μg/day 1α D₃ as the optimum dosage for preventing 2°HPT.

収録刊行物

日本透析療法学会雑誌

日本透析療法学会雑誌 25 (8), 881-885, 1992

社団法人日本透析医学会

詳細情報詳細情報について

CRID: 1390001204675912064

NII論文ID: 130003874394

DOI: 10.4009/jsdt1985.25.881

ISSN: 18846211; 09115889

本文言語コード: ja

データソース種別

JaLC
Crossref
CiNii Articles

抄録ライセンスフラグ: 使用不可

書き出し

問題の指摘